As a finalist in the third round of the SPRIND Challenge “Broad-Spectrum Antivirals”, the iGUARD research project receives follow-up funding.

2.5 million euros for rapid therapies against viral diseases

News /

There are still no effective drugs for most viral diseases. Antiviral therapies are therefore urgently and quickly needed. However, the development of therapeutics can take decades. In the iGUARD (integrated Guided Ultrafast Antiviral RNAi Drug Development) project, a team of researchers from Fraunhofer ITEM and Hannover Medical School (MHH) has set itself the goal of developing customized therapies as quickly as possible. The iGUARD project has already been funded twice by the Federal Agency for Disruptive Innovation as part of the SPRIND Challenge “Broad-Spectrum Antivirals” and, as a finalist in the third and final round of the innovation competition, will now receive a follow-up funding up to 2.5 million euros for the further development of new antiviral agents.